COSA 2015* , ,
Presentations this author is a contributor to:
Baseline predictors of early treatment failure in patients with Platinum Resistant/ Refractory (PRR) and Potentially Platinum Sensitive (PPS) recurrent ovarian cancer (ROC) receiving ≥3 lines of chemotherapy- The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) (#203)
3:00 PM
Peey-Sei Kok
Posters1
Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)? Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). (#167)
3:20 PM
Peey-Sei Kok
Best of the Best Posters - Survivorship & Supportive care